Free Trial

CytoMed Therapeutics (GDTC) Stock Forecast & Price Target

-0.02 (-0.98%)
(As of 07/12/2024 ET)

CytoMed Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

146.31% Upside
High Forecast$5.00
Average Forecast$5.00
Low Forecast$5.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.00$5.00$5.00N/A
Forecasted Upside146.31% Upside150.04% Upside42.05% UpsideN/A
Get CytoMed Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.

GDTC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GDTC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CytoMed Therapeutics Stock vs. The Competition

TypeCytoMed TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside146.31% Upside994.21% Upside9.17% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00 ➝ $5.00+150.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:51 AM ET.

GDTC Forecast - Frequently Asked Questions

What is CytoMed Therapeutics' forecast for 2024?

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for CytoMed Therapeutics is $5.00, with a high forecast of $5.00 and a low forecast of $5.00.

Should I buy or sell CytoMed Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoMed Therapeutics in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GDTC shares.

Does CytoMed Therapeutics's stock price have much upside?

According to analysts, CytoMed Therapeutics's stock has a predicted upside of 150.04% based on their 12-month stock forecasts.

What analysts cover CytoMed Therapeutics?

CytoMed Therapeutics has been rated by research analysts at Benchmark in the past 90 days.

Do Wall Street analysts like CytoMed Therapeutics more than its competitors?

Analysts like CytoMed Therapeutics more than other "medical" companies. The consensus rating for CytoMed Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GDTC compares to other companies.

This page (NASDAQ:GDTC) was last updated on 7/13/2024 by Staff

From Our Partners